The Study on Newly Developed McAb NJ001 Specific to Non-Small Cell Lung Cancer and Its Biological Characteristics

Monoclonal antibody (McAb) is the key tool for cancer immunodiagnosis and immunotherapy. McAb-based immunotherapy that targets tumor antigens has had great achivement. In this study, a cell clone which kept secreting high-titer IgG1-type McAb named NJ001 against human non-small cell lung cancer (NSCLC) cells was obtained. The titer of purified NJ001 was 2×106. The antigen named SP70 of NSCLC specifically identified by NJ001 was proved to be a protein with the relative molecular mass (Mr) of 70 kDa. The results of immunohistochemical staining indicated that NJ001 could positively react to NSCLC, but weak positively or negatively react to human small-cell lung cancer (SCLC), pulmonary pseudotumor and other epithelial tumors. In soft agar assay, the colony formation efficiency in NJ001 groups decreased in a dose-dependent manner. For the concentration of 100 µg/ml, 200 µg/ml and 400 µg/ml, the inhibition ratio of colony formation was 23.4%, 62.5% and 100% respectively. Meanwhile, NJ001 caused significant reduction in tumor volume and tumor weight compared to control mice in lung cancer xenograft model. The tumor growth inhibition ratio in 200 µg, 400 µg and 800 µg NJ001 groups was 10.44%, 37.29% and 44.04%, respectively. NJ001 also led to cytomorphological changes and induced the apoptosis of human lung adenocarcinoma cell line SPC-A1 significantly. The newly developed NJ001 selectively reacted to NSCLC and exhibited anti-tumor activity both in vitro and in vivo. NJ001 is of great value concerning immunodiagnostics and immunotherapy for NSCLC and holds promise for further research regarding the mechanism underlying tumor progression of NSCLC.

[1]  R. Salgia.  Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer , 2011, Cancer.

[2]  S. Batra,et al.  Monoclonal Antibodies Recognizing the Non-Tandem Repeat Regions of the Human Mucin MUC4 in Pancreatic Cancer , 2011, PloS one.

[3]  K. Rabe,et al.  Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung , 2011, British Journal of Cancer.

[4]  C. Borrebaeck,et al.  A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti-tumor activity. , 2011, Glycobiology.

[5]  W. Zong,et al.  Elevated Expression of Squamous Cell Carcinoma Antigen (SCCA) Is Associated with Human Breast Carcinoma , 2011, PloS one.

[6]  G. Ragupathi,et al.  Human Monoclonal Antibodies to Sialyl-Lewisa (CA19.9) with Potent CDC, ADCC, and Antitumor Activity , 2011, Clinical Cancer Research.

[7]  Soldano Ferrone,et al.  Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  N. Bander,et al.  Saporin toxin‐conjugated monoclonal antibody targeting prostate‐specific membrane antigen has potent anticancer activity , 2010, The Prostate.

[9]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[10]  M. Detmar,et al.  Phage-Derived Fully Human Monoclonal Antibody Fragments to Human Vascular Endothelial Growth Factor-C Block Its Interaction with VEGF Receptor-2 and 3 , 2010, PloS one.

[11]  Lihong V Wang,et al.  Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts , 2010, Clinical Cancer Research.

[12]  R. Figlin,et al.  Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape , 2010, Molecular Cancer Therapeutics.

[13]  B. Karger,et al.  Antigen identification and characterization of lung cancer specific monoclonal antibodies produced by mAb proteomics. , 2010, Journal of proteome research.

[14]  Jungang Chen,et al.  A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models , 2010, PloS one.

[15]  Yong-Sung Kim,et al.  A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab. , 2010, Journal of biotechnology.

[16]  Sang‐Gun Ahn,et al.  Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo , 2010, BMC Cancer.

[17]  A. Rossi,et al.  Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. , 2009, The oncologist.

[18]  M. Sliwkowski,et al.  Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms , 2009, Oncogene.

[19]  A. Argyriou,et al.  Recent Advances Relating to the Clinical Application of Naked Monoclonal Antibodies in Solid Tumors , 2009, Molecular medicine.

[20]  L. Crinò,et al.  Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. , 2009, Lung cancer.

[21]  Z. Qian,et al.  Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen , 2009, BMC Cancer.

[22]  Xiao-Cheng Wu,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control , 2008, Journal of the National Cancer Institute.

[23]  Tsutomu Fujimura,et al.  Haptoglobin‐β chain defined by monoclonal antibody RM2 as a novel serum marker for prostate cancer , 2008, International journal of cancer.

[24]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[25]  R. Dillman,et al.  Monoclonal antibodies in cancer therapy: 25 years of progress. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Y. Hooks,et al.  Application of phage display to high throughput antibody generation and characterization , 2007, Genome Biology.

[27]  Janice M. Reichert,et al.  Development trends for monoclonal antibody cancer therapeutics , 2007, Nature Reviews Drug Discovery.

[28]  K. Suzuki,et al.  How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer , 2007, British Journal of Cancer.

[29]  C. Bokemeyer,et al.  A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  F. He,et al.  An alternative strategy for high throughput generation and characterization of monoclonal antibodies against human plasma proteins using fractionated native proteins as immunogens , 2005, Proteomics.

[31]  F. He,et al.  Proteomics‐based generation and characterization of monoclonal antibodies against human liver mitochondrial proteins , 2006, Proteomics.

[32]  M. Kris,et al.  Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma , 2005, Cancer.

[33]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.

[34]  R. Herrmann,et al.  Overview of monoclonal antibodies in cancer therapy: present and promise. , 2005, Critical reviews in oncology/hematology.

[35]  W. El-Deiry,et al.  Overview of cell death signaling pathways , 2005, Cancer biology & therapy.

[36]  M. Teitell,et al.  The evolution of antibodies into versatile tumor-targeting agents. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[38]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Vansteenkiste,et al.  Positron emission tomography in the management of non-small cell lung cancer. , 2004, Hematology/oncology clinics of North America.

[40]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[41]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[42]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.